What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting?
OBJECTIVE
To assess whether osteoporosis education, with and without bone mineral density (BMD) testing, increases the initiation of lifestyle changes and pharmaceutical treatment to prevent osteoporosis.


METHODS
A total of 508 women, aged 54-65, from a large managed care organization who were not on osteoporosis prevention therapy participated in an intervention study. Participants were randomly assigned to either an education class on osteoporosis (n = 301) or education plus BMD (n = 207). A control group of 187 women receiving no intervention were also surveyed to serve as comparison. Group differences and differences based on BMD test result were compared 6 months after education regarding self-reported changes in health behaviors using chi2 tests and logistic regression analyses.


RESULTS
Of the 508 intervention participants, 455 (90%) responded to the follow-up survey. Initiation of hormone replacement therapy was reported by 9%, with 5% reporting starting alendronate. More than half reported changes in diet, exercise, or calcium intake. Forty-three percent increased their vitamin D intake. There were no significant group differences in behavior except with regard to pharmaceutical therapy; subjects with education plus BMD were three times more likely than those receiving education only to report starting hormone replacement therapy (p = 0.004). Low BMD scores were associated with increasing vitamin D intake (p = 0.03) and starting medication (p = 0.001). Women in the intervention groups were significantly more likely to report modifying their diet (p < 0.001), calcium (p < 0.01), and vitamin D intake (p < 0.0001) than women in the control group, not exposed to education.


CONCLUSIONS
Education regarding osteoporosis prevention seems to encourage women to make lifestyle changes. The inclusion of BMD testing enhances the likelihood that women will consider pharmaceutical therapy.
Rolnick
S J
SJ
HealthPartners Research Foundation, Minneapolis, Minnesota 55440-1524, USA.
Kopher
R
R
Jackson
J
J
Fischer
L R
LR
Compo
R
R
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density; D002136:Calcium, Dietary / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008329:Managed Care Programs; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010353:Patient Education as Topic; D017698:Postmenopause; D018570:Risk Assessment; D014807:Vitamin D / Q000008:administration & dosage
D002136:Calcium, Dietary; D014807:Vitamin D; D019386:Alendronate